Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2025)
Historic Current Deferred Revenue for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $5.8 million.
- Stoke Therapeutics' Current Deferred Revenue fell 8176.96% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 8176.96%. This contributed to the annual value of $19.0 million for FY2024, which is 2405.12% up from last year.
- Latest data reveals that Stoke Therapeutics reported Current Deferred Revenue of $5.8 million as of Q3 2025, which was down 8176.96% from $8.7 million recorded in Q2 2025.
- Over the past 5 years, Stoke Therapeutics' Current Deferred Revenue peaked at $31.6 million during Q3 2024, and registered a low of $5.8 million during Q3 2025.
- In the last 4 years, Stoke Therapeutics' Current Deferred Revenue had a median value of $13.5 million in 2023 and averaged $14.8 million.
- As far as peak fluctuations go, Stoke Therapeutics' Current Deferred Revenue soared by 26190.04% in 2024, and later plummeted by 8176.96% in 2025.
- Stoke Therapeutics' Current Deferred Revenue (Quarter) stood at $14.9 million in 2022, then rose by 2.88% to $15.3 million in 2023, then increased by 24.05% to $19.0 million in 2024, then plummeted by 69.65% to $5.8 million in 2025.
- Its Current Deferred Revenue was $5.8 million in Q3 2025, compared to $8.7 million in Q2 2025 and $18.2 million in Q1 2025.